FDA Accepts Andrx’ Corrective Action Plan On Manufacturing Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency’s acceptance means that manufacturing deficiencies will not result in warning letter or consent decree, and will not hold up ANDA approvals, Andrx CEO Rice says.
You may also be interested in...
Andrx’ ANDA Approvals On Hold Pending Resolution Of Manufacturing Issues
The company has been placed in “Official Action Indicated” status following an FDA inspection that resulted in a “Form 483.”
Andrx’ ANDA Approvals On Hold Pending Resolution Of Manufacturing Issues
The company has been placed in “Official Action Indicated” status following an FDA inspection that resulted in a “Form 483.”
Andrx Presents Manufacturing Corrective Action Plan To FDA
Andrx presented FDA with a full action plan to correct manufacturing deficiencies at a recent meeting, the company said